CCL2 and lymphangioma: Collectively, our data show that inhibition of CSF1R, CCL2, or COX-2 limit Pik3ca-driven lymphangiogenesis, suggesting that anti-inflammatory therapy provides a potential therapeutic approach for the treatment of LM.